Skip to main content

Table 3 Changes in metabolic parameters induced by the placebo or pentoxifylline at the end of treatment

From: Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study

 

Placebo (n = 70)

Pentoxifylline (n = 52)

P-value

BMI (kg/m2)

0.22 ± 1.75

−0.25 ± 0.80

0.079

Systolic BP (mmHg)

3.9 ± 18.3

1.3 ± 15.7

0.417

Diastolic BP (mmHg)

0.3 ± 11.8

1.8 ± 10.9

0.473

HbA1c (%)

0.09 ± 0.72

−0.34 ± 0.74

0.002

Fasting plasma glucose (mg/dL)

8.4 ± 37.4

−10.0 ± 38.9

0.009

HOMA-IRa

0.24 ± 2.61

−0.79 ± 2.03

0.041

Hs-CRP (mg/L)

0.70 ± 4.33

0.51 ± 4.32

0.818

Serum TNF-α (pg/mL)

0.14 ± 0.71

−0.24 ± 3.11

0.322

AST(U/L)

0.33 ± 13.33

−1.31 ± 7.84

0.432

ALT(U/L)

−0.30 ± 14.38

−1.37 ± 8.75

0.637

r-GT(U/L)

1.19 ± 25.27

−3.90 ± 8.88

0.126

  1. Data expressed as the means ± standard deviation (SD). P-values are for comparing the absolute change in each variable between the placebo and pentoxifylline groups
  2. aHOMA-IR was measured only in subjects who were not receiving insulin treatment, placebo (n = 58), pentoxifylline (n = 39)
  3. BMI body mass index, BP blood pressure, HbA1c glycated hemoglobin, HOMA-IR homeostatic model assessment insulin resistance, hs-CRP high-sensitivity C-reactive protein, TNF tumor necrosis factor, AST aspartate aminotransferase, ALT alanine aminotransferase, r-GT, r-glutamyl transpeptidase
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us